DefNEtTrp: An Iron Dual Chelator Approach for Anticancer Application

Area of Science:

• Biochemistry and Molecular Biology
• Cancer Therapeutics
• Medicinal Chemistry

Background:

• Targeting iron metabolism is a novel strategy for cancer treatment.
• Iron chelators like deferasirox (Def) and triapine (Trp) inhibit Fe-dependent pathways crucial for cancer cell proliferation and metastasis.
• Triapine (Trp) specifically inactivates iron-dependent ribonucleotide reductase (RNR), essential for DNA replication.

Purpose of the Study:

• To develop a novel dual iron chelator, DefNEtTrp, combining Def and Trp moieties.
• To exploit the high affinity Fe(II/III) binding and redox modulation capabilities of Def and Trp.
• To evaluate the anticancer potential of DefNEtTrp against various cancer cell lines.

Main Methods:

• UV-vis spectroscopy, EPR spectroscopy, ESI and MALDI-TOF mass spectrometry, and cyclic voltammetry were used for characterization.
• Antiproliferative activity was assessed using cytotoxicity assays (IC50).
• Cell death mechanisms, including apoptosis and ferroptosis, were investigated.

Main Results:

• DefNEtTrp demonstrated potent and broad-spectrum antiproliferative activity across different cancer cell lines.
• The dual chelator exhibited superior cytotoxicity (IC50 0.77 ± 0.06 μM) compared to Def (2.6 ± 0.15 μM) and Trp (1.1 ± 0.04 μM).
• DefNEtTrp selectively targeted cancer cells and induced cell death via both apoptosis and ferroptosis.

Conclusions:

• DefNEtTrp is a promising dual iron chelator with significant anticancer properties.
• The compound effectively disrupts cancer cell iron metabolism, leading to potent cytotoxicity.
• DefNEtTrp represents a potential new therapeutic agent for broad-spectrum cancer treatment.